EMA/245670/2013

European Medicines Agency decision

P/0116/2013

of 26 April 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for paclitaxel (Abraxane), (EMEA-001308-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0116/2013

of 26 April 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for paclitaxel (Abraxane), (EMEA-001308-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Celgene Europe Limited on 28 June 2012 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 April 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision refusing a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for paclitaxel (Abraxane), powder for suspension for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for paclitaxel (Abraxane), powder for suspension for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for paclitaxel (Abraxane), powder for suspension for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby refused.

Article 4

This decision is addressed to Celgene Europe Limited, 1 Longwalk Road, Stockely Park, UB11 1DB Uxbridge, Middlesex, United Kingdom.

Done at London, 26 April 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/135312/2013 Corr

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and on the refusal of a waiver

EMEA-001308-PIP01-12

Scope of the application

Active substance(s):

Paclitaxel

Invented name:

Abraxane

Condition(s):

Treatment of solid malignant tumours

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for suspension for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Celgene Europe Limited

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Celgene Europe Limited submitted for agreement to the European Medicines Agency on 28 June 2012 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 9 August 2012.

Supplementary information was provided by the applicant on 17 January 2013. The applicant proposed modifications to the paediatric investigation plan and requested a deferral and a waiver.

A meeting with the Paediatric Committee took place on 11 April 2013.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to refuse the granting of a waiver in accordance with Article 13 of said Regulation, for some of the subsets of the paediatric population and the above mentioned condition(s) as it does not meet the grounds detailed in Article 11(1) of said Regulation.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 12 April 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of solid malignant tumours

The request for the waiver applied to:

- The paediatric population from birth to less than 6 months of age;
- for powder for suspension for injection for intravenous use.

The waiver request does not provide evidence to support the following grounds set out in Article 11(1) of Regulation (EC) No 1901/2006 that:

- (c) the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

Because:

- the disease or condition for which the specific medicinal product is intended, does occur in the paediatric population(s);
- clinical studies may fulfil a therapeutic need of the paediatric population.

The waiver request is therefore refused by the PDCO.

2. Paediatric Investigation Plan

2.1. Condition: treatment of solid malignant tumours

2.1.1. Indication(s) targeted by the PIP

Treatment of a paediatric solid malignant tumour and of chemotherapy-naïve metastatic melanoma

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for suspension for injection

2.1.4. Measures

Area	Number of measures	Description
Quality	1	Measure 1: Development of a vial with age-appropriate dose content
Non-clinical	3	Measure 2: *In vivo* pharmacodynamic study of paclitaxel (formulated as albumin-bound nanoparticles) against Ewing sarcoma, rhabdomyosarcoma, osteosarcoma and neuroblastoma xenografts Measure 3: *In vivo* pharmacodynamic study of paclitaxel (formulated as albumin-bound nanoparticles) against paediatric bone sarcoma xenografts Measure 4: *In vitro* and *in vivo* pharmacodynamic study of paclitaxel (formulated as albumin-bound nanoparticles) in neuroblastoma and sarcoma models
Clinical	3	Measure 5: Open-label, non-controlled, multi-centre trial to evaluate pharmacokinetics, pharmacodynamics, tolerability and safety of paclitaxel (formulated as albumin-bound nanoparticles) in children from 6 months to less than 18 years of age (and adults) with a solid malignant tumour Measure 6: Open-label, randomised, controlled, multi-centre trial with lead-in to evaluate the pharmacokinetics, tolerability, safety and activity of paclitaxel (formulated as albumin-bound nanoparticles) as add-on to best standard of anti-cancer therapy in children from 6 months to less than 18 years of age (and adults) with a recurrent or refractory neuroblastoma or a recurrent or refractory rhabdomyosarcoma Measure 7: Open-label, randomised, controlled, multi-centre trial to evaluate the safety and efficacy of paclitaxel (formulated as albumin-bound nanoparticles) as add-on to best standard of anti-cancer therapy in children from birth to less than 18 years of age (and adults) with a first relapse or high-risk newly-diagnosed neuroblastoma or rhabdomyosarcoma

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of solid malignant tumours

   Authorised indication(s):

   - Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated

Authorised pharmaceutical form(s):

Powder for suspension for infusion

Authorised route(s) of administration:

Intravenous use